THERAPY DOSSIER · th-70b99c75996a

Ademol (1-adamantylethyloxa-3-morpholino-2-propanol hydrochloride)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32672703 ↗2020Reported benefit

EVALUATION OF THE EFFECT OF ADEMOL ON THE DYNAMICS OF NEURON-SPECIFIC ENOLASE IN TRAUMATIC BRAIN INJURY IN RATS.

RatTBIUnspecifiedIntravenous2 mg/kg

Model: Acute experimental traumatic brain injury (model of head injury; induction method not described in the abstract)

Over 8 days, ademol 2 mg/kg and amantadine sulfate 5 mg/kg reduced the rise in neuron-specific enolase relative to the control pathology group by an average of 52.1% and 38.2% respectively; ademol exceeded the reference drug by an average of 22.5%.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…